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SUMMARY
Cancer progresses through distinct stages, and
mouse models recapitulating traits of this progres-
sion are frequently used to explore genetic, morpho-
logical, and pharmacological aspects of tumor devel-
opment. To complement genomic investigations of
this process, we here quantify phosphoproteomic
changes in skin cancer development using the SILAC
mouse technology coupled to high-resolution mass
spectrometry. We distill protein expression signa-
tures from our data that distinguish between skin
cancer stages. A distinct phosphoproteome of the
two stages of cancer progression is identified that
correlates with perturbed cell growth and implicates
cell adhesion as a major driver of malignancy. Impor-
tantly, integrated analysis of phosphoproteomic data
and prediction of kinase activity revealed PAK4-
PKC/SRC network to be highly deregulated in SCC
but not in papilloma. This detailed molecular picture,
both at the proteome and phosphoproteome level,
will prove useful for the study of mechanisms of
tumor progression.
INTRODUCTION
Mouse models of cancer are a resource of great potential in
cancer research and they have provided important insights into
tumor biology (Marcotte and Muller, 2008; Walrath et al.,
2010). They have helped in confirming gene function, identifying
tumor markers, and contributing to a better understanding of the
cellular and molecular mechanisms of tumor initiation and the
multistage processes of tumorigenesis. In addition to detailed
functional studies, these models have been investigated with
large-scale and unbiased ‘‘omics’’ technologies—usually in
the form of measuring gene expression changes with microar-
rays (Hummerich et al., 2006; Landis et al., 2005). However,
messenger RNA (mRNA) levels do not correlate well with protein
levels (Tian et al., 2004) or provide information on protein activity.
Therefore, more advanced large-scale analyses of proteins and
their posttranslational modifications (PTMs) are needed to
understand the complex processes involved in cancer develop-
ment. While this has been a central aim of the proteomics
community, daunting technological challenges have so far pre-
vented proteomics from complementing the ubiquitous genomic
technologies at a similar level of comprehensiveness (Hanash
and Taguchi, 2010; Harsha and Pandey, 2010; Pawson and
Scott, 2005).
Cancer is intimately associated with somatic alterations (Strat-
ton et al., 2009). Mutations that initiate the tumor process often
occur in protein kinase pathways. A prominent example is
a single base mutation of HRas, which strongly impinges on
the Mapk pathways, or the kinase BRaf, which are associated
with a large fraction of epithelial tumors (Davies et al., 2002;
Reddy et al., 1982). Such mutations have direct effects on the
activity of specific signaling pathways, which can in principle
be detected by large-scale analysis of the phosphorylation
status of proteins in tumors (‘‘phosphoproteomics’’). Alterations
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in signaling pathways drive cellular changes, including changes
in gene expression, ultimately resulting in altered protein levels,
which can be measured by quantitative proteomics. Therefore,
proteomics can complement genomic studies that are well
suited to determine alterations in the cancer genome and gene
expression levels.
A well-established system to study tumor progression in mice
is the chemical induced multistage skin carcinogenesis model
(Abel et al., 2009). Beyond the generic advantages of mouse
models, such as reduced genetic variability, this model offers
three distinct stages for proteomic investigation, representing
precancerous, benign and malignant tumors. Here, we use an
advanced proteomic workflow employing high-resolution mass
spectrometry (MS) in combination with stable isotope labeling
by amino acids in cell culture (SILAC) (Mann, 2006; Ong et al.,
2002) to quantify the proteome and the phosphoproteome of
tumor tissues. For phosphoproteomics, we employed an estab-
lished enrichment protocol, which has been used successfully
with SILAC to analyze cell signaling (Olsen et al., 2006). However,
it is still challenging to perform quantitative proteomics studies
in vivo and, to our knowledge, there are to date no quantitative
in-depth studies of the phosphoproteome in vivo in cancer. We
have previously set the stage for such studies by establishing
SILAC labeled mice as a powerful tool to perform in vivo quanti-
tative proteomic studies of organs, tissues, and cells (Kru¨ger
et al., 2008; Ostasiewicz et al., 2010). Additionally, we and others
have shown that phosphorylations can be studied in vivo (Mon-
etti et al., 2011; Rikova et al., 2007; Ville´n et al., 2007; Zanivan
et al., 2008).
In the present paper, we combined the SILAC mouse tech-
nology in a ‘‘spike-in’’ fashion (Geiger et al., 2011) with a chemi-
cal-induced carcinogenesis tumor model. A single treatment of
the skin with the carcinogen DMBA initiates skin carcinogenesis
by inducing an activating mutation of HRas. Further repeated
applications of the tumor promoter 12-O-tetradecanoylphor-
bol-13-acetate (TPA) provoke thedevelopment of a premalignant
lesion, papilloma (Pap). Papilloma mirrors human actinic kera-
tosis (AK) and can progress to the malignant tumor, squamous
cell carcinoma (SCC) (Roberts et al., 2007). We accurately iden-
tified and quantified a considerable part of the proteome and
phosphoproteome of TPA-treated skin (referred to as TPA),
Pap, and SCC. With this approach, we provide evidence that
distinct parts of the proteome and phosphoproteome are regu-
lated during the different steps of carcinogenesis and identify
specific processes that become deregulated. Illustrating the
relevance of this approach to human tumors, we validated
altered expression levels of specific candidates for cancer
progression in human tumor tissues and confirmed their invasive
potential.
RESULTS
SILAC Mouse Model to Quantify Phosphoproteome
in Cancer Progression
We isolated tissue samples from four defined stages of mouse
skin cancer development: (1) non-TPA-treated control skin
(Ctl), (2) TPA-treated skin, (3) lesions that have progressed to
the papilloma stage and finally to the (4) carcinoma stage.
Tumors were classified as Pap or SCC according to histological
analysis and further validated by laminin 332 staining performed
on tissue. As expected, the basement membrane (BM) was well
organized in TPA and Pap, but not in the SCC where the BM
accumulated at the interface between stroma and invading
tumor cells (Figure 1A).
The skin is an elastic tissue rich in collagens and keratins,
making in-depth proteomic analysis very difficult with standard
MS protocols. Indeed, use of lysis buffers containing urea, which
is compatible with MS, resulted in low yields of extracted
proteins and incomplete protease cleavage. Therefore we used
a lysis buffer containing 4% SDS. We separated the proteome
by 1D SDS-PAGE followed by in-gel digestion. For the phospho-
proteome, we also solubilized proteins in SDS, but digested
them on filter (Wisniewski et al., 2009), fractionated by strong
cation exchange chromatography (SCX) and subsequently en-
riched for phosphorylated peptides using titanium dioxide
(TiO2) (Larsen et al., 2005). Peptides were then analyzed with
high-resolution liquid chromatography-tandem mass spectrom-
etry (nLCMS/MS) on a hybrid linear ion trap Orbitrap instrument.
To accurately assign to each protein the expression and phos-
phorylation level, we used a spike-in SILAC approach (Geiger
et al., 2011). For this, a labeled proteome standard with a protein
composition and abundance as similar as possible to the skin
tissue samples to be analyzed was required, and we tested the
suitability of the skin from SILAC mice. We mixed an equal
amount of the SILAC standard lysate to each tissue lysate at
a ratio of 1:1 and processed the samples forMS analysis (Figures
1B and 1C). A comparable number of proteins and phosphoryla-
tion sites were quantified in all the analyzed samples (Figures
S1A and S1B). Additionally, on average, more than 95% of the
quantified proteins and phosphorylation sites in the skin, Ctl or
TPA, were within a 4-fold ratio compared to the SILAC skin. In
the tumors, the percentage was higher than 90% (Figures S1C
and S1D). By ensuring that the large majority of proteins were
in an easily quantified range, these results validate the SILAC
skin as an excellent spike-in standard for accurate proteome
quantification.
From three measurements, which comprised a total of more
than 400 MS runs, we identified 6,536 proteins (Table S1) and
14,985 class I phosphorylation sites (sites with high phospholoc-
alization probability for a single amino acid) (Table S2) with a 0.87
and 0.37 ppm average absolute peptide mass error, respec-
tively. Phosphorylation sites were localized with single amino
acid resolution (median localization probability 0.999) and
comprised 13,173 Ser, 1,708 Thr, and 104 Tyr sites, of which
40% have not been previously reported.
To evaluate the reproducibility of our quantitative approachwe
measured the correlation of the normalized SILAC ratio for
proteins and phosphorylation sites between measurements.
While TPA, Pap, and SCC showed high similarity (average R2
of 0.9 for proteome and 0.8 for phosphoproteome), the correla-
tion was only 0.5 for the control skin (Figures S1E and S1F and
Table S3). This low correlation was attributed to the nonreprodu-
cible isolation of the samples that occurred in the skin samples
alone. Although we included the proteome and phosphopro-
teome of the control skin as a resource of proteins and phos-
phorylation sites identified in themouse skin, we did not consider
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those samples any further for our study, and we estimated pro-
teomic changes in tumors by comparison to TPA.
A total of 3,457 proteins and 5,249 phosphorylation sites were
accurately quantified and used for further bioinformatic analysis
(Tables S4 and S5). This set includes proteins with a large
variety of functions. According to gene ontology (GO) annotation
reported in the UniProt database, 116 proteins and 59 phosphor-
ylated proteins are involved in cell adhesion, 92 proteins and
85 phosphorylated proteins in protein kinase activity, and 38
proteins and 41 phosphorylated proteins in transcription
cofactor activity.
Together, these data show that our screen on TPA-treated
skin and tumor tissues was accurate and reproducible and that
it quantitatively probed the proteome and phosphoproteome to
considerable depths in vivo.
Large-Scale Phosphoproteomics Faithfully
Recapitulates Known Molecular Mechanisms
in Tumorigenesis
The state of dedifferentiation of a tumor is often used to evaluate
its malignancy (Ehrenreiter et al., 2009). As expected, the differ-
entiation markers Krt10 and Krt1 were expressed at substantially
lower levels in SCC compared to TPA and Pap (Tables S1 and
S4). Additionally the expression levels of 25 proteins involved
in skin differentiation (Table S6) (Meves et al., 2011) were signif-
icantly downregulated in SCC (Figure 2A). These included the
desmosomal proteins Dsg1 and Dsg2. Immunofluorescence
staining of mouse tissues with antibody against Dsg1/2 con-
firmed the decreased expression of these proteins in SCC
(Figures 2B and S2A). Interestingly, we found Dsg1/2 downregu-
lated also in tissues from SCC patients (Figures 2C and S2B),
which has been previously observed for SCC of different origin
(Wong et al., 2008). Likewise, a number of other proteins that
showed altered expression levels are known to be regulated in
tumor development (Kurzen et al., 2003), providing a positive
control for our screen.
One of the fundamental traits of cancer cells is their sustained
growth and proliferation often reflected by the deregulation of
cyclin-dependent kinase (CDK), mTOR, and ERK/MAPK path-
ways (Hanahan and Weinberg, 2011). Such alterations are
generally driven by modified phosphorylation levels, of proteins
involved in these pathways. Our phosphoproteome data recapit-
ulate these alterations. Notably, the cell cycle regulator Rb1 can
be inactivated by phosphorylation at Ser800 (pRb1) by Cdk
(Roesch et al., 2005) and thereby promote mitosis. Rb1 has
previously been reported to be highly phosphorylated in SCC
of the DMBA-TPA mouse model and in human SCC (Nilsson
et al., 2004). Our MS analysis found significantly higher levels
A
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Figure 1. SILAC Mouse Skin as Standard for In Vivo Quantitative Phosphoproteomics
(A) Confocal images of frozen sections of TPA, Pap, and SCC stained for laminin 332. Nuclei are stainedwith DAPI (blue). Images are representative of the staining
from three mice. Scale bar, 100mm.
(B) SILAC-based workflow.
(C) MS analysis workflow. Results represent three to five MS measurements. MW, standard molecular weight; S, mixed lysate.
See also Tables S1, S2, and Figure S1.
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Figure 2. Known Processes in Cancer Development Recapitulated by Quantitative Proteomics In Vivo
(A) Whiskers plot (minimum and maximum value) of normalized SILAC ratio of 25 proteins involved in keratinocytes differentiation (see Table S6). 1–3 indicates
the MS measurements. p values were calculated between TPA and SCC of the same set of MS measurement.
(B and C) Quantification of Dsg1/2 immunofluorescence in mouse tissues (B) TPA (n = 5), Pap (n = 5), and SCC (n = 6) and human tissues (C) normal skin (n = 5),
SCC (n = 5). n = number of mice/patients. FI, fluorescence intensity.
(D) Normalized SILAC ratios of phosphorylation sites (substrate) involved in processes deregulated in cancer. For each site, the kinase is indicated. Bars = SD
(n > 2, n = number of quantifications). p values were calculated between Pap/SCC and TPA.
(legend continued on next page)
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of pRb1 in Pap and SCC compared to TPA-treated skin
(Figure 2D), which we confirmed by immunofluorescence
analysis of tissue sections (Figures 2E and 2F). Importantly, we
observed similar results by immunostaining of human skin and
SCC tissue samples (Figures 2G and 2H). Phosphorylation of
Akt1s1 at Ser184 (pAkt1s1) indicates mTOR activity (Wang
et al., 2008). Here, we found pAkt1ts1 levels to increase signifi-
cantly in tumors compared to TPA (Figure 2D). Finally, increased
phosphorylation levels of BRaf at Ser135 were measured,
pointing to elevated activity of the Erk/Mapk pathway (Ritt
et al., 2010) (Figure 2D). These specific examples are only a small
fraction of the several thousand sites quantified. Their validity
serves as a clear indicator of the relevance of our phosphopro-
teomic data set.
Phosphoproteomic Alteration in Skin Carcinogenesis
The SILAC ratios of quantified proteins and phosphorylation
sites were clustered using correlation distances between aver-
ages and this revealed a close similarity between Pap (P) and
SCC (S) but striking differences between TPA (T) and tumor.
Nevertheless, there was a small but distinct subset of proteins
regulated only in SCC (Figures 3A and 3B).
We thus investigated the phosphoproteomic changes during
skin carcinogenesis in more detail. Bymeans of ANOVA test cor-
rected for permutation based false discovery rate (FDR), we
identified proteins and phosphorylation sites significantly regu-
lated in tumors compared to TPA (Tables S4 and S5). Of the
3,457 quantified proteins, 483 and 332 were upregulated in
Pap and SCC, respectively, representing the 10%–14% of the
proteome. Furthermore, 660 and 720 proteins were downregu-
lated, representing the 19%–21% of the proteome (Figure 3C).
Of the 5,249 phosphorylation sites, 825 and 970 were upregu-
lated in Pap and SCC, respectively, while 720 and 1,017 were
downregulated (Figure 3D). This indicated that 14%–16% of
the phosphoproteome was upregulated, whereas 18%–19%
downregulated. As anticipated by the hierarchical clustering,
5% of the proteins and phosphorylation sites were regulated
only in the SCC (Figures 3C and 3D).
When we combined the phosphoproteome and proteome
data sets, we found that we could measure the corresponding
protein abundance for 45% of the quantified phosphorylation
sites (Figure 3E). For half of these sites, protein and phosphory-
lation levels were regulated accordingly, while for the other half
significant regulation occurred only at the level of phosphoryla-
tion (Figure 3F). Only 1% of the phosphorylation sites showed
opposite regulation at the protein and phosphorylation levels.
This subset included the tumor-regulated pyruvate kinase
(Pkm2), which was found upregulated at the protein level, but
with decreased phosphorylation level of Ser127.
Altogether these data show that one-third of the proteome and
phosphoproteome of the skin and tumor tissues are expressed
at different levels, that there are detectable proteomic differ-
ences between benign and malignant tumor tissues, and that
a complementary analysis of proteome and phosphoproteome
in our study is necessary for a more comprehensive under-
standing of the molecular mechanisms in carcinogenesis.
Functional Portrait of Skin Carcinogenesis
To gain insights on the processes regulated in skin cancer
progression, we identified the GO categories (Figures 4A and
4B and Table S7) overrepresented in proteins regulated in Pap
and SCC compared to TPA. Most of the categories covered
major pathways deregulated in cancer such as cell cycle, tran-
scription, translation, apoptosis, cell adhesion, and metabolic
process. Additionally, this analysis revealed a prominent fraction
of proteins with catalytic, binding, and structural activities. This
suggested that functional and physical protein-protein interac-
tions are highly regulated during cancer development and we
therefore visualized this information in a systematic way in the
STRING environment (Szklarczyk et al., 2011). Since cell adhe-
sion is a prominent process involved in cancer development,
and overrepresented in SCC (Figure 4A), we integrated detailed
information from the literature (Table S8) into the STRING
analysis and visualized the results in Cytoscape. We built up
color-coded networks with stage-related information (Figures
S3A and S3B). As expected, tightly connected subnetworks
emerged, where most of the proteins were already regulated in
the Pap stage (Figure 4C). Downregulated subnetworks clearly
highlighted altered metabolism. Notably, tumor cells switch their
metabolism to anaerobic glycolysis (Ohlrogge et al., 2009).
Accordingly, the pyruvate dehydrogenases (Pdha1, Pdhb)
reduced expression levels in Pap and SCC compared to TPA.
Conversely, Ldha and Pkm2, key enzymes for the synthesis of
lactate, increased expression levels (Table S4). Also glutathione,
retinol and lipid metabolisms were found downregulated.
Interestingly, components of the latter were downregulated
specifically in the SCC. Finally, a major subnetwork included
cell adhesion proteins. The subnetworks extracted from up-
regulated proteins and phosphorylation sites revealed a clear
difference between benign and malignant tumor and distinct
connections between phosphorylation and proteome changes.
For example, the cell cycle-related subnetwork involved more
phosphorylation than protein expression changes that occurred
already in the Pap, while the DNA replication complex Mcm 2-7
was upregulated only in the SCC stage. Also proteins involved in
nuclear transport were found regulated at phosphorylation level
already in the Pap. Similarly, RNA binding proteins were regu-
lated at the phosphorylation level but formed a cluster with ribo-
somal subunits, which were regulated at the expression level. In
contrast, apoptosis was regulated only at the protein level, like-
wise for proteins involved in the immune system. As for the
downregulated proteins, some changes were found in metabolic
pathways, including glutathione and nucleotide metabolism.
Finally, cell adhesion proteins formed a predominant subnet-
work. Itgb1, Itga1, Rac2, Vasp, Src, and fibronectin (Fn1) were
identified as cell adhesion hubs with higher number of edges
(E and G) Representative immunofluorescence of pRB1 in mouse (E) and human (G) Ker14+ cells. Scale bar, 50 mm.
(F and H) Quantification of immunofluorescence of pRB1 in TPA, Pap and SCC mouse (E), and skin and SCC human (G) tissue sections. The quantification is
based on the number of positive nuclei per 100 Krt14+ cells (y axis). * = p < 0.05 (n = 5).
See also Figure S2.
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(Figure S3C) and therefore used to extract the cell adhesion
subnetwork (Figure 4C). Strikingly, with the exception of Fn1,
all of them, as well as most of their first neighbors, were signifi-
cantly regulated only in the SCC stage. A detailed investigation
of the protein identity of this highly connected adhesion
subnetwork unveiled proteins tightly associated to the actin
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Figure 3. Proteomic and Phosphoproteomic Differences between Skin and Tumor Tissues
(A and B) Heatmaps and hierarchical clustering of quantified proteins (A) and phosphorylation sites (B). Some clusters of proteins and phosphorylation sites
expressed at higher (red) or lower (blue) levels in SCC compared to Pap are highlighted, and a zoom is provided. Heatmap colors represent themedian (proteome
nR 2; phosphoproteome nR 3) of the SILAC ratio.
(C and D) Number of proteins (C) and phosphorylation sites (D) significantly up (Upreg) or downregulated (Downreg) in Pap and SCC compared to TPA. ‘‘Only
SCC’’ indicates proteins and phosphorylations sites regulated in SCC but not in Pap.
(E) Percentage and number (in brackets) of phosphorylation sites with protein expression level quantified or not.
(F) Comparison between protein expression and phosphorylation levels for the 45% phosphorylation sites in (E). Proteins and phosphorylation sites were
considered regulated according to ANOVA test.
See also Tables S4 and S5.
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cytoskeleton, for example, Vcl, Vasp, Lasp1, Tes, Lima1, and the
kinases Src, Pak1, Pak2, and Pak4. Confirming these results,
immunofluorescence staining for Vasp and Lima1 on mouse
tissues gave stronger staining in SCC compared to Pap and
TPA (Figure 5A). Likewise, we observed more intense staining
for VASP and LIMA1 in human SCC compared to skin and AK
(Figure 5B). Interestingly, Pak4 showed increased phosphoryla-
tion levels of the phosphorylation site Ser181, which we have
previously identified in melanoma tissue samples (Zanivan
et al., 2008). Ser181 is located within the linker region of Pak4,
suggesting a regulatory function that might be interesting to
explore in the future.
Apart from providing a systems level analysis of tumor devel-
opment, the combined evidence from significantly altered
protein and phosphorylation levels highlights a prominent role
of cell adhesion mechanisms in the progression of skin carci-
noma. Although the concept is not novel (Yu et al., 2011), we
identify here a specific subset of highly connected adhesion
proteins that potentially contribute to tumor malignancy.
Similarity between Proteomic Changes in Mouse
and Gene Expression in Human SCC
Gene expression changes at the mRNA level have been previ-
ously measured in two independent studies where normal skin
(n = 6) was compared to cutaneous SCC (n = 5) biopsies (Nindl
et al., 2006), and normal skin (n = 4) to SCC (n = 11) tissue
samples from patients (Riker et al., 2008). We analyzed the
concordance of message level changes in human SCC
compared to normal skin and the mouse proteomic changes in
SCC compared to TPA. We matched the significant mRNA
changes against the corresponding protein changes (Table
S9), and Figures 5C and 5D show a positive correlation between
the two analyses. As specific examples, GPDL1 and ACACB
were downregulated at the protein and gene expression levels,
in both microarray data sets, while, the intermediate filament
KRT16 and the actin-binding protein fascin (FSCN1) were upre-
gulated. Interestingly, FSCN1 has been shown to be involved in
several types of SCC (Alam et al., 2012), but not yet skin SCC.
Immunofluorescence on mouse and human tissues confirmed
high levels of FSCN1 in SCC (Figures 5E–5H).
These results show significant molecular similarities between
cutaneous SCC in human patients and in the mouse model
used in our study and corroborate the relevance of our proteomic
study to provide hints in skin cancer progression in humans.
Predicted Kinase Activities in Skin Carcinogenesis
Phosphoproteomic data are a unique resource to determine
kinase activity in biological samples, and we interrogated the
825 and 720 phosphorylation sites upregulated in Pap and
SCC, respectively, to identify potential deregulated kinases
during skin carcinogenesis. By using Motif-X (Schwartz and
Gygi, 2005), we identified 13 linear kinase motifs significantly
enriched in the Pap and 12 in the SCC. Proline-directed phos-
phorylations were the major regulated class in both tumors.
Also motifs containing acidic amino acids were common to
Pap and SCC. Conversely, some motifs were stage specific,
such as an additional acidic motif in Pap and motifs containing
arginine and lysine in SCC (Figure 6A). To predict the kinases
responsible for the phosphorylation of these motifs, we used
a prepublication version of the NetworKIN algorithm, where
we included the analysis of the 163 kinases identified in our
phosphoproteomic study (Jørgensen et al., 2009). Of those,
29 were inferred with significant activity (Figure 6B). For
comparison, we included the predicted substrates for a data
set containing more than 60,000 observed phosphorylation sites
(MegaPhospho). Several proline-directed kinases of the ERK/
MAPK, CDK, and GSK3 families and CK2, whose phosphoryla-
tion motif contains acidic amino acids, were identified as major
tumor-regulated classes. Additionally, as expected, PKC, which
is activated upon TPA treatment (DiGiovanni, 1992), was pre-
dicted to be highly active in the tumors. Similar predictions
were found for PKA and PKD. Interestingly, all of them showed
higher predicted activity in SCC compared to Pap, supporting
the finding that the arginine-containing motif (PKs motifs may
contain an arginine at position 2 or 3) was enriched in SCC
but not in Pap (Figure 6A). These results confirmed the patterns
observed with Motif-X and pinpointed the likely kinases involved
based on cellular context information. Furthermore, the Networ-
KIN algorithm predicted Pak1, Pak2, and Pak4 to be active
in tumors. PAK proteins regulate cell adhesion and are
involved in the development of several tumors (Molli et al.,
2009), and we investigated them further. The autophosphoryla-
tion sites of Pak1 and Pak2, Ser144 and Ser141, respectively,
which contribute to Pak kinase activation (Chong et al., 2001),
increased phosphorylation level during tumor progression (Table
S5). In contrast, Ser181 of Pak4, which is a not yet functionally
characterized site, conserved in human, showed similar phos-
phorylation levels in Pap and SCC, and we investigated PAK4
predicted activity in more detail. Based on observed phospho-
proteomic data and kinase activity predictions, we isolated the
PAK4 subnetwork (Figure 6C), which unveiled that PAK4 phos-
phorylates RAF1 (Ser43) and SRC (Ser17) in SCC but not in
Pap. Intriguingly the network predicted that also PKCalpha
and PKCdelta phosphorylate SRC (Ser12) only in the SCC.
While phosphorylation of RAF1 at Ser43 has been suggested
as feedback phosphorylation that negatively regulate RAF1
(Dougherty et al., 2005), phosphorylation at Ser17 and Ser12 acti-
vate SRC tyrosine kinase activity (Gould and Hunter, 1988). All
together, these observations support that SRC activity is
increased in skin SCC compared to benign tumor and that this
may be triggered by augmented activity of the protein kinases
PAK4 and PKC.
Figure 4. Functional and Physical Interaction in Skin Carcinogenesis
(A and B) GO biological processes (A) and molecular functions (B) overrepresented in up- and downregulated proteins in Pap and SCC.
(C) STRING subnetworks of proteins and phosphorylated proteins down (downregulation) and upregulated (upregulation) in SCC. For downregulation, apart for
the cell adhesion subnetwork, all the others are related to metabolic processes indicated in brackets. The node color represents regulation at the protein
expression level (Prot), while the node border color represents the regulation at the phosphorylation level (Phos) in the Pap and SCC stages.
See also Tables S7, S8, and Figure S3.
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Figure 5. Comparison Human Microarrays with Mouse Proteome
(A and B) Confocal images of mouse (A) and human (B) tissue sections stained for LIMA1 and VASP. Nuclei are stained with DAPI (blue). AK, actinic keratosis.
Scale bar, 50 mm.
(legend continued on next page)
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Invasive Role of Phosphoproteins Regulated in Skin
Carcinogenesis
To explore the functional relevance of our phosphoproteomic
study, we performed invasion assays using the human carci-
noma cell lines A431 and SCC9. We chose three cell adhesion
proteins for validation: VASP and FSCN1 as they are upregulated
in skin SCC (Figure 5), and PAK4, as it is predicted to promote
SRC activity in skin SCC. Cells were efficiently silenced for
FSCN1, VASP, and PAK4 (Figure S4) and their invasiveness
was assessed in a 3D collagen-based invasion assay and a 3D
organotypic invasion assay. Strikingly, the silencing of FSCN1,
VASP, or PAK4 significantly reduced invasion of A431 (Figures
7A and 7B) and SCC9 (Figures 7C and 7D) compared to cells
silenced with the nontargeting small interfering RNA (siRNA)
(Figures 7 and S4), indicating that these proteins are part of the
invasive machinery of SCC cells.
These results show the functional relevance of our proteomic
study in unraveling the proteins, which regulate tumor cell inva-
sion, and that further exploration of our data set might identify
potential drug targets for therapies.
DISCUSSION
Here, we have investigated proteome changes in defined stages
of skin cancer development. Following upon previous large-
scale studies of tumor development at the level of the genome
and the transcriptome, the expression levels and phosphoryla-
tion status of thousands of proteins have now been accurately
quantified throughout cancer progression in a challenging in vivo
system. Apart from the SILACmouse technology, this wasmade
possible by enormous improvements in all aspects of the high-
resolution quantitative proteomics pipeline over the last few
years. Many protein and phosphorylation changes contained in
our data set have already been described in the literature, and
thus provide an excellent validation of our screen. These addi-
tional regulated protein and phosphorylation changes represent
a valuable resource for the cancer research community.
Systems-level analysis of our phosphoproteomic data clearly
showed that the depth of coverage and quantitative accuracy
were sufficient to generate a functional portrait and infer kinase
activities of the carcinogenesis process.
The accurate quantification of the proteome of the skin and
tumor tissues highlightedmajor differences in protein expression
levels. This may be partly due to the diverse composition of the
tissues, such as a higher proportion of dermis in the skin, as
suggested by collagen I and skeletal muscle proteins expression
levels (Table S3). Such differences were not found between
Pap and SCC and therefore were irrelevant for the com-
parison between tumors. Additionally, the higher expression
levels of the integrin heterodimer amb2, fibrinogen, and several
complement components suggested the presence of inflamma-
tory and blood cells in the tumor tissue. Nevertheless, our
proteomic analysis identified clear and distinct differences in
protein expression levels between normal keratinocytes and
tumor cells (Figures 2 and 5), validating the suitability of our
data sets for unveiling molecular mechanisms associated with
skin carcinogenesis.
Deregulated Processes in Skin Carcinogenesis
Dedifferentiation is a key feature of cancer development, often
used to classify tumors. In our study, we found several compo-
nents of desmosomes, which are multiprotein complexes that
maintain tissue integrity and cell-cell adherence in epithelial
tissue, with altered expression levels at the stage of malignancy.
By extension, other proteins in our data set that are downregu-
lated specifically in the SCC stage may be novel markers of
dedifferentiation and cancer progression.
A key characteristic of cancer is deregulated cell growth and
our data revealed broad upregulation of the protein translation
machinery already at the Pap stage. Instead, increased phos-
phorylation levels were associated with regulators of translation
and gene expression. Interestingly, the Mcm 2-7 complex,
involved in DNA replication initiation and elongation during cell
cycle, was highly expressed only in the SCC, indicating further
deregulation in malignancy. Metabolism was another major
regulated cellular function and changes were already character-
istic in benign tumors. In particular, our proteomic data recapit-
ulate the well-knownmetabolic shift to anaerobic glycolysis, also
known as the Warburg effect (Ohlrogge et al., 2009), which we
found with different levels of regulation in cancer. For instance,
we found upregulation of Pkm2 expression level but downregu-
lation of a specific phosphorylation site. Additionally, we
observed changes in the retinol metabolism pathway. Retinol
has been shown to be crucial in regulating cell differentiation
and induction of antiproliferative genes and retinoid therapy
has proven successful to suppress tumor formation in the two
stage skin cancer mouse model and several solid tumors in
human (Cheepala et al., 2009; Njar et al., 2006). Changes in the
redox capacity of cancer cells are well known, and we found
that proteins involved in glutathione metabolism changed
expression levels already in the Pap.
The BMsurrounding the tumor cells is remodeled during tumor
progression, and BM components can drive tumor malignancy.
Laminin 332 is the major BM component expressed in SCC
where it regulates cancer cell motility, and its expression level
correlates with tumor invasion and patient prognosis (Marinko-
vich, 2007). In our DMBA-TPA skin carcinogenesis model, lami-
nin 332 had increased expression levels and aberrant deposition
in SCC compared to TPA and Pap (Figure 1). Likewise, the major
laminin 332 receptor integrin b1 was upregulated specifically in
SCC as most of the proteins of the cell adhesion subnetwork.
Intriguingly, most of these proteins, including Fscn1, are
(C and D) From two independent microarray studies, Nindl et al. (2006) (C) and Riker et al. (2008) (D), the ratios of mRNAs significantly regulated in SCC compared
to normal skin in patients are plotted against the ratio calculated in our proteomic study. The percentage in each quadrant indicates the fraction of mRNA
significantly regulated also at the protein level. Red, upregulated in SCC; blue, downregulated in SCC, S, Spearman rank correlation.
(E and G) Confocal images of mouse (E) and human (G) tissue sections stained for FSCN1. Scale bar, 78.3 mm (E) and 50 mm (G).
(F and H) Quantification of (E) and (G).
See also Figure S3 and Table S9.
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Figure 6. Kinase Activities in Tumors
(A) Heatmap of the linear kinase motifs enriched in Pap and SCC according to Motif-X. Motifs are divided into categories based on the amino acidic composition:
proline-directed (yellow), acidic (blue), basic (red), and other (gray).
(B) Kinases predicted to be active in Pap and SCC (p value according to Mann-Whitney Wilcoxon test). On the y axis is represented the percentage of phos-
phorylated substrates predicted for each kinase.
(C) Extended PAK4 subnetwork, including phosphorylation sites annotation, in Pap and SCC.
562 Cell Reports 3, 552–566, February 21, 2013 ª2013 The Authors
functionally and physically connected to the actin cytoskeleton
that is a critical regulator of cancer cell motility and invasion.
We provide functional evidence that at least Fscn1, Vasp, and
Pak4 can regulate SCC cell invasion. These proteins have previ-
ously been shown to regulate tumor cell migration and invasion.
It is therefore tempting to speculate that laminin 332, through
integrin b1, can activate a specific module of adhesion proteins
that regulates the cytoskeletal remodeling needed for cell
invasion.
Phosphoproteome Dynamics in Skin Carcinogenesis
Our combined phosphoproteomic data provided a unique
opportunity to assess the signaling status of different tumor
stages. Because uncontrolled activity of protein kinases is
amajor tumor-driving cause, we focused our analysis on upregu-
lated phosphorylation sites. Enrichment analysis of substrate
motifs together with prediction of kinase activity revealed that
specific kinases were associated to the different stages of skin
cancer development. MAPK, CDK, and GSK3 activity was
common to Pap and SCC, CK1/2 was higher in Pap, whereas
PKA, PKC, PKD, and PAK activity was higher in the malignant
SCC stage. In depth investigation of the predicted PAK4 and
PKC kinase activity discovered that PAK4, PKCalpha, and
PKCdelta may promote SRC activity only in SCC. We and others
have previously shown that increased Src expression levels in
the DMBA-TPA mouse model increases tumor incidence and
burden (Matsumoto et al., 2003; Meves et al., 2011). Our current
phosphoproteomic study sheds light on the molecular mecha-
nisms that might be causative to increased SRC activity,
whereby PAK4 and PKCs play prominent roles. Furthermore,
PAK4 has already been shown to regulate ovarian cancer cell
proliferation through a PAK4/SRC/EGFR pathway and that
expression levels contribute to poor prognosis in cancer (Siu
et al., 2010). We show here that PAK4 regulates SCC cell inva-
sion and our results thus open an exciting perspective to inves-
tigate PAK4 in invasion and as a target for anticancer therapies in
skin SCC.
In summary, the experimental setup and the mouse model
used in this study provides important advantages for the proteo-
mics quantification and interpretation of the results. Applications
of the ‘‘spike-in’’ SILAC technology used here (Geiger et al.,
2011) should help to extend this approach to other mouse tumor
models and human tumors. Moreover, proteomic findings from
the mouse model can be verified in human samples using stan-
dard techniques (as shown in this study). In particular, it will be
interesting to verify the functional importance of the cell adhe-
sion proteins and the PAK4-PKC/SRC subnetwork, which
our proteomic data strongly highlighted, in human samples.
Likewise, it will be attractive to assess if our findings of specific
phosphoproteomic signaling patterns associated with particular
stages of tumor development can be generalized to other
tumors. Our results clearly imply that it will be fruitful to
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Figure 7. Cell Invasion Inhibition by Gene Silencing of FSCN1, VASP, and PAK4
(A) Phase contrast of the invading front of collagen-embedded spheroids composed by A431 cells transfected with nontargeting siRNA (siCTL) or siRNA targeting
FSCN1, VASP, and PAK4. The red line indicates where cells start to invade. Error bars = SEM (n = 3). Scale bar, 100mm.
(B) Quantification of (A).
(C) Immunofluorescence of the invading front of SCC9 cells into skin tissue (3D organotypic invasion assay). SCC9 cells were transfected with siCTL or siRNA
targeting FSCN1, VASP, and PAK4.
(D) Quantification of (C). Error bars = SEM (n = 3).
p value is according to Mann-Whitney test, single tail. **p = < 0.0001, *p = 0.05. See also Figure S4.
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interrogate the signaling status of tumors using advanced pro-
teomic technologies.
EXPERIMENTAL PROCEDURES
Tumor Generation and SILAC Mice
Cutaneous two stage chemical carcinogenesis was performed in FVB/N mice
as previously described (Roberts et al., 2007). The SILAC mouse colony was
generated by fully labeling C57BL/6 mice with 13C6 lysine (lysine 6) containing
diet (SILANTES) as previously described (Kru¨ger et al., 2008; Zanivan et al.,
2012). See also Extended Experimental Procedures.
Mice were housed under the approval and the institutional guidelines gov-
erning the care of laboratory mice of the local government of upper Bavaria
and in compliance with National and International laws and policies.
Sample Preparation and MS Analysis
Non-TPA-treated and TPA-treated skin, Pap and SCC tumor tissue samples
were collected from FVB/N mice of two independent DMBA-TPA experi-
ments. Dissected tissues were homogenized, lysed in 4% SDS, 100 mM
DTT, 100 mM Tris HCl lysis buffer. and mixed 1:1 with SILAC skin lysate.
For each MS measurement, we pooled tissues collected from 3-6 different
mice. Digested peptides were identified on a LTQ-Orbitrap Velos (Thermo
Scientific), experiment 1 and 2, or LTQ-Orbitrap Elite (Thermo Scientific),
experiment 3. The MS data were processed using the MaxQuant software
(Cox and Mann, 2008) and searched with the Andromeda search engine
(Cox et al., 2011) against the mouse UniProt database. Only proteins with at
least one peptide uniquely assigned to the respective sequence were consid-
ered identified. Phosphorylations were assigned as previously described
(Olsen et al., 2006). The relative quantification of the peptides and proteins
against their SILAC-labeled counterparts was performed by MaxQuant.
Quantified proteins (3,457) and phosphorylation sites (5,249) used for the bio-
informatic analysis included (1) proteins with a maximum of one missing
quantification value within the three MS measurements; (2) phosphorylation
sites quantified in at least three MS measurements (Tables S4 and S5). MS
RAW data are available on the public repository Tranche. See also Extended
Experimental Procedures.
Significantly Regulated Proteins and Phosphorylation Sites
For ANOVA analysis, MS measurements of the same tissues, TPA, Pap, and
SCC, were grouped together and the statistical test corrected with permuta-
tion based FDR was done with FDR < 0.05 and S0 = 1 as previously described
(Tusher et al., 2001). Regulated proteins and phosphorylation sites were
considered upregulated or downregulated if the effect size was a positive or
negative number, respectively.
Functional and Physical Connections for the Skin Carcinogenesis
Portrait
The Uniprot IDs of proteins and phosphorylated proteins regulated in the SCC
stage were used to query STRING (Szklarczyk et al., 2011). Two different
queries were performed, one for down and one for upregulated proteins. In
the latter query, we included actin interactions according to literature data
and annotated to the integrin adhesome (Zaidel-Bar and Geiger, 2010), where
we assigned to each ITGA and ITGB the specific integrin subunit according to
the reference given in the integrin adhesome table (Table S8). The following
parameters were used: active prediction methods: experiments, databases,
and neighborhood; required confidence (score): high confidence. STRING-
determined interactions were visualized in Cytoscape (Cline et al., 2007),
and proteins colored according to the stage (Figures S3A and S3B). Cytoscape
was also used to generate the connection map where nodes were colored
according to the number of edges (Figure S3C). The cell adhesion subnetwork
was generated by extracting the nodes with highest number of edges (>12)
among the adhesion-related proteins and their first neighbor nodes.
Category Enrichment and Kinase Analysis
GO (Ashburner et al., 2000) analysis has been performed using PantherDB
(Mi et al., 2010).
Significantly overrepresented linear kinase motifs were determined by
querying the sequence motifs (Table S4) of the phosphorylation sites upregu-
lated in Pap and SCC with Motif-X (Schwartz and Gygi, 2005) against the IPI
mouse database, using a p value of E-6 and a minimum number of occur-
rences of 20.
To predict the kinase activity in the two tumor stages, we used NetworKIN
(version 3.0) (see Linding et al., 2007 and R.L. and E.M.S., unpublished
data), which can predict substrates for 222 kinases, based on both the linear
motifs of the kinase catalytic domain (NetPhorest algorithm [Miller et al.,
2008]) and the network context of the kinases. The mouse sequences were
matched to the homologous human sequences, and predictions on the up-
and downregulated phosphorylation sites in Pap and SCC were generated in
the human background. The analysis was performed only on kinases with
experimentally identified peptides. The kinase activity enrichment was calcu-
lated as ratio between the number of sites predicted by specific kinase and the
number of sites identified and quantified in the sample.
To determine significance, the Mann-Whitney Wilcoxon test (p < 0.05) was
applied. The MegaPhospho contains 64,232 manually curated phosphoryla-
tion sites, integrating (Dinkel et al., 2011) and PhosphositePlus (Hornbeck
et al., 2012).
Extended PAK4-centric subnetworks were constructed using the identified
and quantified phosphorylation sites in the Pap and SCC samples, for which
the regulating kinases were predicted using NetworKIN v3.0. Kinases pre-
dicted to interact directly were used in the analysis, including their predicted
substrates. A score threshold of 0.1 was applied, and the top 30% of predic-
tions were used. The signaling networks were visualized in Cytoscape.
Microarray Analysis and Comparison with the Proteome
Affymetrix Cel files were normalized and analyzed in Partek Genomics
Suite Software, version 6.5. Multiarray Averaging (RMA) method of microarray
normalization and summarization was followed by log2 and quantile transfor-
mations of the data. Multiway ANOVA was used to identify significantly
regulated genes from one of the experimental groups and linear contrasts
performed between all pairs of experimental conditions. Multiple test correc-
tions were performed for all calculated p values. Less conservative step
up p value was used for further selection of significantly differentially ex-
pressed genes.
Chi square and Spearman rank correlation were calculated based on the
logarithmized ratio between the median of SCC and skin samples.
Collagen Invasion Assay
3D collagen gel invasion assay was set up as previously described (Lu et al.,
2010) with minor modifications (see Extended Experimental Procedures).
3D Organotypic Invasion Assay
The 3D organotypic invasion assays were performed essentially as previously
described (Ridky et al., 2010) with modifications (see Extended Experimental
Procedures).
Immunofluorescence
Immunostainings have been performed according to standard protocols.
Details are reported in the Extended Experimental Procedures.
Statistical Analysis
Unless indicated otherwise, p values have been calculated using a two tail
Mann-Whitney test using GraphPad Prism. *p < 0.05; **p < 0.01.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, ten tables, and Extended
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.01.003.
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